Tenth of Ramadan Pharmaceutical Industries & Diagnostic-Rameda

As of June 30, 2026, Tenth of Ramadan Pharmaceutical Industries & Diagnostic-Rameda carries a market capitalization of 10.06B, placing it among publicly traded companies globally. Its enterprise value stands at 12.36B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Tenth of Ramadan Pharmaceutical Industries & Diagnostic-Rameda's next confirmed earnings release is scheduled for December 2, 2026.

As of June 30, 2026, Tenth of Ramadan Pharmaceutical Industries & Diagnostic-Rameda has 2.03B shares outstanding.

As of June 30, 2026, Tenth of Ramadan Pharmaceutical Industries & Diagnostic-Rameda trades at a trailing price-to-earnings ratio of 28.10. The price-to-sales ratio is 2.12, and the price-to-book ratio stands at 4.32.

As of June 30, 2026, Tenth of Ramadan Pharmaceutical Industries & Diagnostic-Rameda trades at an EV/EBITDA multiple of 10.06 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.82 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 10.84 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Tenth of Ramadan Pharmaceutical Industries & Diagnostic-Rameda trades at an EV/FCF ratio of 30.13, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 12.36B versus a market cap of 10.06B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Tenth of Ramadan Pharmaceutical Industries & Diagnostic-Rameda maintains a current ratio of 1.21, meaning it holds 1.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 99.15, indicating elevated leverage, while an interest coverage ratio of 2.38 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Tenth of Ramadan Pharmaceutical Industries & Diagnostic-Rameda posted a return on equity (ROE) of 15.18, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 18.56 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 6.27, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 15.82, useful for judging operating efficiency across full business cycles. The company generates approximately 2.43M in revenue per employee across its workforce of 1,805.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.89 indicates how many times Tenth of Ramadan Pharmaceutical Industries & Diagnostic-Rameda sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Tenth of Ramadan Pharmaceutical Industries & Diagnostic-Rameda recorded 126.29M in income tax expense. That works out to an effective tax rate of 27.54, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 458.53M, leaving 330.86M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Tenth of Ramadan Pharmaceutical Industries & Diagnostic-Rameda's stock has gained approximately 48.72% over the past 52 weeks. The 50-day moving average sits at 5.81, while the 200-day moving average is 4.81.

Over the twelve months ended June 30, 2026, Tenth of Ramadan Pharmaceutical Industries & Diagnostic-Rameda generated 4.39B in revenue and converted that into 330.86M in net income, yielding earnings per share of 0.18. EBITDA reached 1.23B, while operating income came in at 1.07B.

As of June 30, 2026, Tenth of Ramadan Pharmaceutical Industries & Diagnostic-Rameda holds 104.85M in cash and equivalents against 2.35B in total debt, resulting in a net debt position of 2.17B. Total book value stands at 2.33B, with working capital of 644.09M providing operational flexibility.

Tenth of Ramadan Pharmaceutical Industries & Diagnostic-Rameda produced 295.76M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -259.19M in capital expenditures, free cash flow totaled 36.56M - equivalent to 0.02 per share.

Over the twelve months ended June 30, 2026, Tenth of Ramadan Pharmaceutical Industries & Diagnostic-Rameda posted a gross margin of 49.77, reflecting its pricing power and cost economics. The operating margin of 24.28 and net profit margin of 7.54 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Tenth of Ramadan Pharmaceutical Industries & Diagnostic-Rameda paid dividends of 0.09 per share. The dividend payout ratio of 47.85 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 0.39, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 0.51, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Tenth of Ramadan Pharmaceutical Industries & Diagnostic-Rameda shareholders.

Tenth of Ramadan Pharmaceutical Industries & Diagnostic-Rameda's most recent stock split took place on December 3, 2025 with a 584:773 split ratio.

As of June 30, 2026, Tenth of Ramadan Pharmaceutical Industries & Diagnostic-Rameda has an Altman Z-Score of 4.16, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.